Form 4: Ovid Therapeutics CEO Jeremy Levin Acquires Additional Shares

Ovid Therapeutics CEO Jeremy Levin purchased 18,248 shares of common stock at an average price of $2.76.

Summary

• On March 18, 2024, Jeremy M. Levin, CEO of Ovid Therapeutics Inc., acquired 18,248 shares of common stock.
• The shares were purchased at a weighted average price of $2.76, with individual prices ranging from $2.76 to $2.78.
• Following the transaction, Levin directly owns 3,616,715 shares of Ovid Therapeutics Inc.
• Levin also has indirect ownership of 35,461 shares through Divo Holdings, LLC, where his spouse is the manager.
• Levin disclaims beneficial ownership of the shares held by Divo.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of insider trading activity. The CEO's purchase is a slightly positive signal, but not significantly impactful on its own.

Positives

• The CEO's purchase of shares may signal confidence in the company's future prospects.

Management Comments

• The Reporting Person disclaims beneficial ownership of the shares held by Divo and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance.

Related Party Transactions

• Indirect ownership of shares through Divo Holdings, LLC, managed by the Reporting Person's spouse.

Stakeholder Impact

• The CEO's stock purchase could have a minor positive impact on shareholder confidence.

Key Dates